References
- Liao T, Su T, Huang L, et al. Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. Scand J Gastroenterol. 2022;57(1):85–90.
- Feng LH, Su T, Lu Y, et al. A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery. Scand J Gastroenterol. 2022;57(5):581–588.
- Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–487.
- Cloyd JM, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr. 2020;9(4):440–451.
- Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol. 2021;13:17588359211018047.
- Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259(2):204–212.
- Ye L, Ye H, Zhou Q, et al. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: new proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. Int J Surg. 2016;29:108–117.
- Zhang XF, Xue F, Wu Z, et al. Development and validation of a modified eighth AJCC staging system for primary pancreatic neuroendocrine tumors. Ann Surg. 2022;275(6):e773–e80.
- Al-Toubah T, Strosberg J. Progress in TNM staging of pancreatic neuroendocrine tumors. Hepatobiliary Surg Nutr. 2021;10(2):238–240.
- Fazio N, Spada F, Bertani E. Looking for the right TNM staging system for pancreatic neuroendocrine tumors. Hepatobiliary Surg Nutr. 2021;10(3):382–384.